---
figid: PMC7404843__RMV-9999-na-g001
figtitle: Immune responses and immunotherapy strategy in SARS‐CoV‐2 infection
organisms:
- NA
pmcid: PMC7404843
filename: RMV-9999-na-g001.jpg
figlink: pmc/articles/PMC7404843/figure/rmv2123-fig-0001/
number: F1
caption: Immune responses and immunotherapy strategy in SARS‐CoV‐2 infection. Immune
  response to SARS‐CoV‐2 involving innate and adaptive immunity. A1, SARS‐CoV‐2 enters
  the host cells by binding the receptor for angiotensin converting enzyme 2 (ACE2).
  The infected cells then release interferon type I (IFN‐α/β); innate immune cells
  respond to the IFNs by establishing an antiviral state. In case of severe infection,
  the viruses are sensed by monocytes, tissue macrophages, and resident dendritic
  cells resulting in uncontrolled proinflammatory cytokine (IFN, TNF‐α, IL‐1β, and
  IL‐6) production, leading to a phenomenon called the cytokine storm, which damages
  the host’s respiratory epithelial cells. Exhausted natural killer cells with increased
  expression of the inhibitory receptor, NKG2A, are also seen in SARS‐CoV‐2. A2, In
  SARS‐CoV‐2 infection, increased antibody production and poor T cell responses are
  observed (A2). CD4+ T cell and CD8+ T cell numbers decrease, and the exhausted phenotype,
  which is characterized by a higher expression of inhibitory receptors, such programmed
  death receptor‐1 (PD‐1) and cytotoxic T lymphocyte associated antigen‐4 (CTLA‐4),
  is seen. Immunotherapy strategies for SARS‐CoV‐2 have been proposed. B1, Transferring
  convalescent sera with neutralizing antibodies from the recovered patients. The
  antibodies can directly bind to SARS‐CoV‐2 and prevent the virus from infecting
  new cells (neutralization), enhance phagocytosis (opsonization), recruit complement
  to lyse infected cells or neutralize the viruses, and promote NK cell mediated killing
  of infected cells through antibody dependent cellular cytotoxicity (ADCC). B2, IFN
  α/β bind to IFN receptors and induce an antiviral response by expressing several
  interferon stimulated genes (ISGs), such as PKR, OAS, and Mx. The protein product
  of ISGs controls viral infection. (B3) The IL‐6R inhibitor (such as tocilizumab)
  binds to the membrane bound IL‐6 receptor (mIL‐6R) and soluble IL‐6 receptor (soluble
  IL‐6R). Binding of tocilizumab to IL‐6R inhibits the IL‐6 signaling pathway
papertitle: Immunopathology and immunotherapeutic strategies in severe acute respiratory
  syndrome coronavirus 2 infection.
reftext: Synat Keam, et al. Rev Med Virol. 2020 Jul 9 :10.1002/rmv.2123.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9107565
figid_alias: PMC7404843__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC7404843__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7404843__RMV-9999-na-g001.html
  '@type': Dataset
  description: Immune responses and immunotherapy strategy in SARS‐CoV‐2 infection.
    Immune response to SARS‐CoV‐2 involving innate and adaptive immunity. A1, SARS‐CoV‐2
    enters the host cells by binding the receptor for angiotensin converting enzyme
    2 (ACE2). The infected cells then release interferon type I (IFN‐α/β); innate
    immune cells respond to the IFNs by establishing an antiviral state. In case of
    severe infection, the viruses are sensed by monocytes, tissue macrophages, and
    resident dendritic cells resulting in uncontrolled proinflammatory cytokine (IFN,
    TNF‐α, IL‐1β, and IL‐6) production, leading to a phenomenon called the cytokine
    storm, which damages the host’s respiratory epithelial cells. Exhausted natural
    killer cells with increased expression of the inhibitory receptor, NKG2A, are
    also seen in SARS‐CoV‐2. A2, In SARS‐CoV‐2 infection, increased antibody production
    and poor T cell responses are observed (A2). CD4+ T cell and CD8+ T cell numbers
    decrease, and the exhausted phenotype, which is characterized by a higher expression
    of inhibitory receptors, such programmed death receptor‐1 (PD‐1) and cytotoxic
    T lymphocyte associated antigen‐4 (CTLA‐4), is seen. Immunotherapy strategies
    for SARS‐CoV‐2 have been proposed. B1, Transferring convalescent sera with neutralizing
    antibodies from the recovered patients. The antibodies can directly bind to SARS‐CoV‐2
    and prevent the virus from infecting new cells (neutralization), enhance phagocytosis
    (opsonization), recruit complement to lyse infected cells or neutralize the viruses,
    and promote NK cell mediated killing of infected cells through antibody dependent
    cellular cytotoxicity (ADCC). B2, IFN α/β bind to IFN receptors and induce an
    antiviral response by expressing several interferon stimulated genes (ISGs), such
    as PKR, OAS, and Mx. The protein product of ISGs controls viral infection. (B3)
    The IL‐6R inhibitor (such as tocilizumab) binds to the membrane bound IL‐6 receptor
    (mIL‐6R) and soluble IL‐6 receptor (soluble IL‐6R). Binding of tocilizumab to
    IL‐6R inhibits the IL‐6 signaling pathway
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ACE2
  - IFNA1
  - IL6
  - IL18
  - TNF
  - KLRC1
  - IFN1@
  - IFNA2
  - IFNA17
  - IFNA4
  - IFNA5
  - IFNA6
  - IFNA7
  - IFNA8
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA21
  - IFNB1
  - IFNAR2
  - IFNAR1
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - LINC00689
  - MYCBP2
  - ADRA1D
  - ATP2A2
  - IL6R
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CTLA4
  - CD8A
  - CD8B
  - CD4
  - IL6ST
  - NM
  - LRPPRC
  - SARS-CoV-2
---
